Zain Ebrahim
Stock Analyst at J.P. Morgan
(0.85)
# 3,739
Out of 4,421 analysts
30
Total ratings
31.3%
Success rate
-6%
Average return
Main Sectors:
Stocks Rated by Zain Ebrahim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Sell | 1,700p | $1,941.00 | -12.42% | 20 | Jun 9, 2026 | |
| EPA: EAPI Euroapi S.A. | Maintained: Hold | €1.70 | $1.24 | +36.66% | 1 | May 13, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Maintained: Buy | 2,400p → 2,000p | $1,473.00 | +35.78% | 2 | Mar 3, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Hold | kr 1,650 → kr 2,050 | $1,653.67 | +23.97% | 2 | Dec 8, 2025 | |
| LON: OXB Oxford Biomedica plc | Maintained: Hold | 550p | $602.00 | -8.64% | 1 | Dec 8, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 675.00 | $495.00 | +36.36% | 1 | Jul 28, 2025 | |
| SWX: BANB Bachem Holding AG | Maintained: Buy | CHF 74.00 → CHF 85.00 | $68.60 | +23.91% | 3 | Jul 25, 2025 |
GSK plc
Jun 9, 2026
Maintained: Sell
Price Target: 1,700p
Current: $1,941.00
Upside: -12.42%
Euroapi S.A.
May 13, 2026
Maintained: Hold
Price Target: €1.70
Current: $1.24
Upside: +36.66%
Hikma Pharmaceuticals PLC
Mar 3, 2026
Maintained: Buy
Price Target: 2,400p → 2,000p
Current: $1,473.00
Upside: +35.78%
Genmab A/S
Dec 8, 2025
Maintained: Hold
Price Target: kr 1,650 → kr 2,050
Current: $1,653.67
Upside: +23.97%
Oxford Biomedica plc
Dec 8, 2025
Maintained: Hold
Price Target: 550p
Current: $602.00
Upside: -8.64%
Lonza Group AG
Jul 28, 2025
Maintained: Buy
Price Target: CHF 675.00
Current: $495.00
Upside: +36.36%
Bachem Holding AG
Jul 25, 2025
Maintained: Buy
Price Target: CHF 74.00 → CHF 85.00
Current: $68.60
Upside: +23.91%